CANCER
Cancer changes the lives of millions of people and families every year, leaving behind millions of stories and millions of questions still unanswered. But what if one of the internet’s most powerful cultures—meme culture—was used not just for entertainment, but to bring attention to one of humanity’s greatest challenges? CANCER is an internet experiment built around that idea. It is not a drug, a biotech company, or a project claiming to have solved cancer; CANCER is an idea, a meme, and a global narrative created to bring attention to cancer research.
The Numbers & Rewards
Fully diluted valuation, live from Robinhood chain DEX.
Paid out automatically to eligible $CANCER holders to date.
Bought back from liquidity pool and burned permanently.
How it compounds
Four continuous steps in a perpetual loop. Hold $CANCER, transaction fees pool directly inside the smart contract, and once the reserve hits 1 $MRNA it triggers immediate distribution and buyback — repeating endlessly.
• Hold 50K $CANCER
Fifty thousand $CANCER in your private wallet is the threshold to be an eligible holder. Hold it and you are permanently enrolled.
• Collect Trading Fees
Every buy and sell pays a fee into the treasury pool automatically — zero gas wasted claiming, nothing staked, no lockups.
▲ Accumulate 1 $MRNA
The contract collects rewards until hitting 1 $MRNA. Reaching this milestone triggers instant autonomous execution.
⚡ Rewards & Burn
*Eligibility requires an active minimum balance of 50,000 $CANCER tokens in eligible Robinhood Chain wallets.
Research Vault
EXPLORE PROTOCOL ARTIFACTS & ARCHITECTURE
Moderna is now overvalued after cancer vaccine-led stock surge, Rothschild & Co. says
Wall Street analysts evaluate recent milestone advances in personalized mRNA cancer vaccines alongside key clinical partner Merck.
Inside Moderna and Merck's cancer vaccine triumph
How mRNA technology and immunotherapy combined to create a landmark breakthrough in personalized cancer treatment trials.
The Cancer Vaccine Gold Rush Has Begun. So Has the Race for Picks and Shovels.
Tempus AI could capture a lucrative slice of Moderna and Merck’s personalized cancer therapy business, with tumor sequencing reaching pivotal clinical scale.